However, its use is complicated by the fact that neprilysin degrades a number of other vasoactive peptides in the circulation, e.g., glucagon, substance P, and bradykinin, which can cause hypotension and angioedema (McMurray et al., 2014) and raises concerns about long-term adverse effects through accumulation of potentially pathogenic peptides (e.g., amyloid-β) (Galo et al., 2020). Here, MME is linked to angioedema.